1056 results about "Virus resistance" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention discloses a bovine I-type alpha interferon-ferritin fusion protein, a mutant thereof, a preparation method and an application of the bovine I-type alpha interferon-ferritin fusion protein. The bovine I-type alpha interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that the expression level, the structural stability and the antiviral activity of the interferon are remarkably improved. The fusion protein is further subjected to single-site or multi-site rational design mutation, and a mutant with significantly improved antiviral activity and stability is obtained. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles have application prospects in preparation of drugs or reagents for preventing or treating bovine viral diseases.

The invention relates to a method for inhibiting in-vitro infection of a porcine epidemic diarrhea virus by using JPH203 and application. The JPH203 can be used for preparing an antiviral drug for inhibiting infection of the porcine epidemic diarrhea virus. JPH203 with the concentration of 5 [mu] M is added in the process that Vero cells are infected with PEDV, compared with a control group without JPH203, the virus infection condition, the protein expression quantity, the RNA content and the virus titer of the PEDV in a treatment group with JPH203 are all remarkably reduced, and it is indicated that JPH203 can be used for inhibiting in-vitro infection of the porcine epidemic diarrhea virus.

The invention discloses a bacteriostatic and antiviral bamboo pulp paper-based sanitary isolation bag as well as a preparation method and application thereof, and belongs to the field of functional paper-based packaging materials. The isolation bag takes bamboo pulp fiber paper as a base material, and the surface of the isolation bag is coated with a water-based polyhydroxyalkanoate functional coating. According to the preparation method, a special polyphenol derivative-chitosan quaternary ammonium salt-nano zinc oxide organic-inorganic hybrid factor is introduced, and the problem of agglomeration of nano particles is effectively solved by utilizing the special bridging effect of polyphenol, so that high-density cation capture and oxidation inactivation sites are constructed on the surface of the coating. Compared with the prior art, the method has the advantages that the method does not need to depend on organic fluorine compounds, and the excellent waterproof and oil-proof barrier effect and the efficient inactivation of viruses can be achieved only through the extremely low coating amount. In addition, the isolation bag has unique environmental chemical responsiveness, can be efficiently dissociated under the alkaline condition to facilitate repulping recovery, can be completely biodegraded in the natural environment, and perfectly considers the requirements of biological safety protection and green environmental protection.

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The invention relates to antiviral application of a membrane fusion inhibition polypeptide. The membrane fusion inhibition polypeptide is used for treating diseases caused by virus infection of pneumoviridae.

The invention discloses a method for quickly rescuing bovine coronavirus epidemic strains and application of the method. The bovine coronavirus SHZ isolate is subjected to efficient segmented cloning, the obtained segment and a Linker sequence are subjected to a cyclic polymerase extension reaction, and the obtained reaction product can be directly transfected to 293T cells for virus packaging without purification. Different from a traditional method, the method does not need to amplify full-length virus cDNA clone by means of bacteria and yeast, but directly obtains a sufficient amount of preliminary products through PCR, and avoids the problems of instability and low efficiency when partial sequences of a virus genome proliferate in a bacteria or yeast host. By adopting the reverse genetic system, the recombinant bovine coronavirus expressing the foreign protein is successfully rescued, a brand new technical platform is provided for dynamic visualization research of in-vivo and in-vitro replication of the virus, and an efficient and flexible tool is also provided for virology research, development of virus vector vaccines and screening of antiviral drugs.

The invention discloses sgRNAs of a specific targeting grass carp RIOK3 gene and a construction method and application of an RIOK3 gene knockout cell line, and belongs to the technical field of gene engineering. The invention provides sgRNAs of a specific targeting grass carp RIOK3 gene and a sequence of a primer group, and also provides a method for constructing a large-fragment knockout cell line of the RIOK3 gene in combination with the sgRNAs, and application of the gene knockout cell line in research on an anti-virus infection mechanism of grass carp. The invention discloses the construction of the grass carp gene in-vitro research model by knocking out the antiviral negative regulatory factor RIOK3 of the fish cells by using the CRISPR-Cas9 technology for the first time, provides an in-vitro research material and a new way for the analysis of an antiviral immune regulation molecular mechanism of the grass carp, and particularly has important guiding significance for the research of resisting grass carp reovirus infection.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention relates to the technical field of anti-enterovirus medicines, in particular to application of Enractevir in preparation of an anti-enterovirus medicine. According to the invention, efficient screening of candidate drugs is realized through a multi-channel virus reporting system based on a TAT trans-activation effect, and a small molecule compound drug Enractevir with a specific antiviral effect on enterovirus group A 71 and enterovirus group D 68 is obtained. Enractevir improves the interferon secretion level of host cells by inhibiting the activity of enterovirus 2A / 3C protease, thereby inhibiting virus replication and proliferation. Enractevir plays a role through double-target 2A / 3C protease, and the risk of virus drug resistance can be reduced. According to the technical scheme, the technical problem that in the prior art, specific drugs for the two kinds of enteroviruses are lacked can be solved, a standardized treatment scheme is provided for prevention and control of enterovirus related diseases in the global range, and the medicine has remarkable public health significance and wide application and popularization value.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention belongs to the technical field of medicines, and provides a method for screening a mutant strain and a high-virulence Seneca virus A mutant strain. The method for promoting Senecavirus A mutation provided by the invention comprises the following steps: inserting an RNAi target sequence between 3Dpol and a 3'untranslated region of an SVA starting strain; the target sequence of the RNAi contains a complementary sequence of an endogenous sequence of the miRNA. According to the research, mutagenesis is carried out on SVA by constructing a high RNAi pressure system, and a method for screening the mutant strain SVA is carried out by simulating an antiviral RNAi mechanism in a host, so that a natural evolution process of the virus is better met, a large number of stably inherited mutant strains can be obtained, and an efficient research and development means is provided for vaccine research and development aiming at the virus.

The invention discloses a modified silicon nitride non-woven fabric and a preparation method and application thereof, and belongs to the technical field of silicon nitride non-woven fabrics. The invention provides a silicon nitride non-woven fabric. The silicon nitride non-woven fabric comprises a non-woven fabric base material and chitosan quaternary ammonium salt-alpha-phase silicon nitride composite particles loaded on the surface of the non-woven fabric base material, the chitosan quaternary ammonium salt-alpha-phase silicon nitride composite particles are formed by combining chitosan quaternary ammonium salt and hydroxylated alpha-phase silicon nitride through hydrogen bonds and coordinate bonds. According to the silicon nitride non-woven fabric, the antiviral inactivation efficiency can be greatly improved, and thorough inactivation of viruses is achieved; the dispersity of alpha-phase silicon nitride particles is obviously improved, and the air permeability of the non-woven fabric is guaranteed; the adhesive force of the particles and a base material is enhanced, and long-acting and stable antiviral performance is The virus contact time is prolonged, and the physical puncture effect is enhanced; the material has excellent biocompatibility, adapts to medical scenes, can be safely applied to medical protection products, such as medical masks and protective garments, which are in direct contact with a human body, and has both safety and practicability.

The invention provides a probiotic composition for improving immunity and a preparation method thereof, and belongs to the technical field of probiotics. The preparation method comprises the following steps: fermenting selenium-enriched nostoc sphaeroides through selenium-enriched saccharomycetes to extract selenium-enriched nostoc sphaeroides polysaccharide and selenium-enriched nostoc sphaeroides protein peptide, mixing with traditional Chinese medicine polysaccharide obtained by extracting astragalus membranaceus, rhodiola rosea, codonopsis pilosula and pseudo-ginseng, and reacting with ferric salt to prepare a polysaccharide-Fe / selenium compound; solid residues are mixed and fermented, and active protein peptide is prepared from the solid residues and selenium-rich nostoc sphaeroides protein peptide; the probiotic composition capable of improving immunity is prepared by extracting a polysaccharide-Fe / selenium compound and a polysaccharide-Fe / selenium compound through an organic solvent, extracting a permeate through an organic solvent to obtain an active component, collecting a bacterial liquid, mixing and embedding the bacterial liquid in the polysaccharide-Fe / selenium compound and sodium alginate, and uniformly mixing the bacterial liquid with the active protein peptide, the active component, taurine and ginsenoside Rg3, so that the probiotic composition capable of improving immunity can play good anti-inflammatory, anti-oxidation, immunoregulation, anti-tumor, anti-virus and other roles, and has a good application prospect. Wide application prospects are realized.

The invention discloses an SOD2 knockout cell line and application of the SOD2 knockout cell line in anti-poxvirus, and relates to the technical field of antiviral research. According to the invention, sgRNA of targeted superoxide dismutase 2 (SOD2) is designed, the sequence of the sgRNA is shown as SEQ ID NO.1-SEQ ID NO.2, then a stable SOD2 knockout human-derived non-small cell lung cancer A549 cell line is established by combining CRISPR / Cas9 gene editing with a lentiviral vector delivery technology, single-cell cloning is obtained through multiple rounds of puromycin screening, and the SOD2 gene knockout A549 cell strain is successfully constructed. Vaccinia virus Tian Tan strain infection shows that the number of plaques of SOD2 knockout cells is obviously greater than that of the plaques (about 2.3 times) of normal cell infection, and the plaques are relatively large, so that fine SOD2 has the effect of limiting intercellular transmission of poxvirus. The invention lays a foundation for research and preparation of antiviral drugs.

The invention discloses an application of Micropterus salmoides Piscidin polypeptide in preparation of an anti-fish virus drug. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 2 or SEQ ID NO. 3. The research finds that the micropterus salmoides Piscidin is an antibacterial peptide with an antiviral function, the polypeptide synthesized by the artificially synthesized micropterus salmoides Piscidin has the characteristic of inhibiting fish DNA virus replication, has a remarkable inhibiting effect on fish iridovirus replication at low concentration, and can be applied to preparation, research and development of fish antiviral drugs. Research of the antibacterial peptide has important scientific value and application value for further research and development of disease-resistant functional gene products.

The invention relates to the technical field of food biology, and discloses an antiviral cubilose polysaccharide active component enriched with bound sialic acid as well as a preparation method and application of the antiviral cubilose polysaccharide active component. The weight-average molecular weight of the cubilose polysaccharide active component is 30-36 kDa, the molecular weight distribution coefficient is 1.1-1.2, the content of bound sialic acid is greater than or equal to 24.0%, and the content of total sugar is greater than or equal to 57.0%. The preparation method comprises the following steps: pretreating a cubilose raw material in a boiling water bath, and sequentially carrying out alkaline protease and neutral protease enzymolysis; carrying out alcohol precipitation on supernate, redissolving, and carrying out papain enzymolysis; and after enzyme deactivation, adjusting the ethanol concentration to 75-85%, precipitating, and drying. According to the method, the cubilose polysaccharide can be efficiently enriched, the combined sialic acid structure of the cubilose polysaccharide is reserved, and the obtained component has the effects of resisting oxidation, inhibiting pathogenic microorganisms and regulating intestinal microecology.

The invention belongs to the field of drug antivirus, and particularly discloses broad-spectrum antiviral application of punicalagin, the punicalagin has a structure shown in a formula 1, is good in stability and low in biological toxic and side effects, and can be used for developing novel broad-spectrum antiviral drugs.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

The invention discloses a nano antibody for resisting feline panleucopenia virus VP2 protein and application of the nano antibody, and belongs to the technical field of antiviral drugs. The nucleotide sequence of the nano antibody is SEQ ID NO: 1, the amino acid sequence of the corresponding code is SEQ ID NO: 2, the yield of the nano antibody reaches 2.05 mg / mL, and the purity of the nano antibody reaches 90%. The nano antibody can react with feline panleucopenia virus and recombinant VP2 protein thereof, can inhibit virus replication on FK81 cells, and can be applied to preparation of drugs for preventing and / or treating feline panleucopenia. By combining the advantages of the nano-antibody and an efficient yeast expression system, the efficient and specific nano-antibody for resisting the feline panleucopenia virus VP2 protein, which can be produced in a large scale, is successfully developed, and the nano-antibody has important scientific research value and clinical application prospect; particularly, a new solution is provided for prevention and treatment of feline panleucopenia.

The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.

The invention relates to the technical field of medicines, in particular to application of green alga-based carbon quantum dots in preparation of chikungunya virus infection resisting drugs or decontamination agents. The green algae-based carbon quantum dots belong to nano materials, and the green algae-based carbon quantum dots prepared by a hydrothermal method are good in water solubility, high in stability and high in biocompatibility. The application of the green alga-based carbon quantum dots in the chikungunya virus infection resisting medicine or decontamination agent is reported, the in-vivo and in-vitro antiviral effect is good, the application is reported for the first time internationally, and a new scheme is provided for prevention and treatment of chikungunya heat.

This invention provides an antiviral sulfated mulberry leaf oligosaccharide, its preparation method, animal feed, and applications, belonging to the field of oligosaccharide technology. The invention involves microwave degradation and H2O2-Vc degradation of mulberry leaf polysaccharides, followed by sulfation modification of the degradation products to obtain sulfated mulberry leaf oligosaccharides. Experiments have shown that adding sulfated mulberry leaf oligosaccharides to feed for aquaculture can promote the growth of largemouth bass, improve feed utilization, antioxidant capacity, lipid metabolism, immune function, and enhance resistance to viral infections.

The invention provides micropterus salmoides Hepcidin-1 (Ms-Hepcidin-1) and an application of a synthetic polypeptide of the micropterus salmoides Hepcidin-1 in preparation of an anti-fish virus drug. The research finds that the Ms-Hepcidin-1 synthetic polypeptide has a remarkable antiviral effect and is a novel antibacterial peptide with a function of inhibiting fish viruses. The Ms-Hepcidin-1 synthetic polypeptide and the recombinant eukaryotic expression vector of the Ms-Hepcidin-1 synthetic polypeptide can obviously reduce the transcription level of MCP, MMP and DNMT genes and the MCP protein level of LMBV, inhibit the replication of the LMBV and reduce the virus titer, and have an obvious fish virus resisting effect. Moreover, the polypeptide synthesized by Ms-Hepcidin-1 is simple to prepare, low in cost, safe to use and convenient to preserve, can be used as a novel antiviral functional gene product to prepare antiviral drugs for fishes, and has important significance on prevention and control of fish iridovirus diseases.

The invention belongs to the technical field of construction methods of disease animal models, and particularly relates to a construction method and application of a renal syndrome hemorrhagic fever mouse model. According to the HTNV infected mouse model established by the method disclosed by the invention, the symptom of the experimental mouse is close to the clinical symptom of a severe hemorrhagic fever with renal syndrome after challenge, the complete lethality and repeatability are high, and the HTNV infected mouse model has the advantages of simple operation, low cost and high efficiency. The method can be used for research on the HTNV pathogenic mechanism and immune mechanism and research and development of antiviral drugs and vaccines, and has great application value for perfecting an HTNV full-chain prevention and control system.

Nucleotide compositions, recombinant vectors, and recombinant viral genomes are disclosed that include a modified horseradish peroxidase (HRP) gene sequence, as well as recombinant viruses that have the modified HRP gene sequence incorporated into the viral genome thereof. The recombinant viruses are utilized in an HRP-based assay to analyze the neutralization potential of candidate antiviral agents, such as antiviral antibodies.